Calidi Biotherapeutics
CLDI
25 hedge funds and large institutions have $525K invested in Calidi Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 3 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
48% more capital invested
Capital invested by funds: $354K → $525K (+$171K)
19% more funds holding
Funds holding: 21 → 25 (+4)
0.36% more ownership
Funds ownership: 0.03% → 0.39% (+0.36%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$217K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.2K |
| 3 |
VF
Virtu Financial
New York
|
+$31.3K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$26.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$31.9K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$28.4K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$2.12K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
| 5 |
JP Morgan Chase
New York
|
-$14 |
CLDI Hedge Fund Activity: Q4 2025 in Review
25 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q4 2025, worth a combined $525K — up 48% from $354K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CLDI positions and 3 closed out — a net gain of 4 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $217K. The largest seller was Belpointe Asset Management, cutting an estimated $31.9K.
- 25 institutional investors held Calidi Biotherapeutics (CLDI) as of Q4 2025, up from 21 in Q3 2025.
- Funds reported $525K of Calidi Biotherapeutics stock for Q4 2025, up 48% quarter-over-quarter.
- 7 funds opened new Calidi Biotherapeutics positions in Q4 2025 and 3 closed out, a net change of +4 holders.
- The largest Calidi Biotherapeutics buyer in Q4 2025 was DRW Securities, an estimated $217K added.
- The largest Calidi Biotherapeutics seller in Q4 2025 was Belpointe Asset Management, an estimated $31.9K sold.
Based on aggregated 13F filings for Q4 2025.